Amber Therapeutics

Incontinence affects more than 200m globally. It’s a debilitating condition that can destroy a person’s social health. Yet treatment options remain decades behind – most are invasive, ineffective, or both.

Amber Therapeutics is developing the world’s first fully implantable, closed-loop neuromodulation therapy for mixed urinary incontinence. By targeting the pudendal nerve via a minimally invasive procedure, their intelligent system restores natural bladder function, offering a transformative new standard of care.

Founded by OSE Entrepreneur-in-Residence Aidan Crawley, alongside Oxford professor Tim Denison, Antwerp professor Stefan De Wachter, and Queen Mary University of London professor Charles Knowles, Amber pairs breakthrough science with bold commercial vision to tackle one of medicine’s most under-addressed challenges.